TY - JOUR
T1 - HDAC inhibitors for muscular dystrophies: Progress and prospects
AU - Sandoná, M.
AU - Consalvi, S.
AU - Tucciarone, L.
AU - Puri, P. L.
AU - Saccone, Valentina
PY - 2016
Y1 - 2016
N2 - lntroduction: Depression is responsible for the most part of the personal and socio-economie burden
due to psychiatric disorders. Since antidepressant response clusters in families, pharmacogenetics
represents a meaningful tool to previde tailored treatments and improve the prognosis of depression.
Areas covered: This review aims to summarize and discuss the pharmacogenetics of antidepressant
drugs in major depressive disorder, with a focus on the most repl icated genes, genome-wide association
studies (GWAS), but also on the findings provided by new and promising analysis methods. In
particular, multimarker tests such as pathway analysis and polygenic risk scores increase the power of
detecting associations compared to the analysis of individuai polymorphisms. Since genetic variants are
not necessarily associated with a change in protein level, gene expression studies may previde
complementary information to genetic studies. Finally, the pharmacogenetic tests that have been
investigated for clinica! application are discussed.
Expert opinion: Despite the lack of widespread clinica! applications, preliminary resu lts suggest that
pharmacogenetics may be useful to guide antidepressant treatment. The US Food and Drug
Administration included pharmacogenetic indications in the labeling of several antidepressants. This
represented an important official recognition of the clinica! relevance of genetic polymorphisms in
antidepressant treatment.
AB - lntroduction: Depression is responsible for the most part of the personal and socio-economie burden
due to psychiatric disorders. Since antidepressant response clusters in families, pharmacogenetics
represents a meaningful tool to previde tailored treatments and improve the prognosis of depression.
Areas covered: This review aims to summarize and discuss the pharmacogenetics of antidepressant
drugs in major depressive disorder, with a focus on the most repl icated genes, genome-wide association
studies (GWAS), but also on the findings provided by new and promising analysis methods. In
particular, multimarker tests such as pathway analysis and polygenic risk scores increase the power of
detecting associations compared to the analysis of individuai polymorphisms. Since genetic variants are
not necessarily associated with a change in protein level, gene expression studies may previde
complementary information to genetic studies. Finally, the pharmacogenetic tests that have been
investigated for clinica! application are discussed.
Expert opinion: Despite the lack of widespread clinica! applications, preliminary resu lts suggest that
pharmacogenetics may be useful to guide antidepressant treatment. The US Food and Drug
Administration included pharmacogenetic indications in the labeling of several antidepressants. This
represented an important official recognition of the clinica! relevance of genetic polymorphisms in
antidepressant treatment.
KW - Duchenne Muscular Dystrophy
KW - HDAC inhibitors
KW - Duchenne Muscular Dystrophy
KW - HDAC inhibitors
UR - http://hdl.handle.net/10807/207533
U2 - 10.1517/21678707.2016.1130617
DO - 10.1517/21678707.2016.1130617
M3 - Editorial
SN - 2167-8707
VL - 4
SP - 125
EP - 127
JO - Expert Opinion on Orphan Drugs
JF - Expert Opinion on Orphan Drugs
ER -